X
<

Why Investors Are Piling In on UniQure in 2018

PART:
1 2 3 4
Why Investors Are Piling In on UniQure in 2018 PART 1 OF 4

Analyst Ratings for UniQure and Its Peers in April 2018

Company overview

UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.

Analyst Ratings for UniQure and Its Peers in April 2018

Interested in FOLD? Don't miss the next report.

Receive e-mail alerts for new research on FOLD

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Analysts’ recommendations

Of the six analysts covering UniQure in April 2018, two of them have given the stock a “strong buy” rating, and four have given it a “buy.” The mean rating for the stock is 1.67 with a target price of $31.90.

Peer ratings

Of the seven analysts covering Amicus Therapeutics (FOLD) in April 2018, three of them have given it a “strong buy” rating, and three have given it a “buy.” One analyst has given it a “hold.” The mean rating for the stock is 1.71 with a target price of $19.93.

Of the 20 analysts covering Spark Therapeutics (ONCE) in April 2018, four of them have given the stock a “strong buy” rating, and ten have given it a “buy.” Five analysts have given it a “hold” rating, and one has given it a “strong sell.” The mean rating for the stock is 2.2 with a target price of $70.05.

Of the 13 analysts covering Voyager Therapeutics (VYGR) in April 2018, five of them have given the stock a “strong buy” rating, and five have given it a “buy.” Three analysts have given it a “hold.” The mean rating for the stock is 1.85 with a target price of $31.46.

In the next part of this series, we’ll take a look at UniQure’s research pipeline.

X

Please select a profession that best describes you: